DK0774005T3 - Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi - Google Patents

Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi

Info

Publication number
DK0774005T3
DK0774005T3 DK95927025T DK95927025T DK0774005T3 DK 0774005 T3 DK0774005 T3 DK 0774005T3 DK 95927025 T DK95927025 T DK 95927025T DK 95927025 T DK95927025 T DK 95927025T DK 0774005 T3 DK0774005 T3 DK 0774005T3
Authority
DK
Denmark
Prior art keywords
reoriented
enzymes
surface expression
prodrug therapy
prodrug
Prior art date
Application number
DK95927025T
Other languages
Danish (da)
English (en)
Inventor
Caroline Joy Springer
Richard Chester Beatty Marais
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of DK0774005T3 publication Critical patent/DK0774005T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
DK95927025T 1994-07-27 1995-07-27 Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi DK0774005T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415167A GB9415167D0 (en) 1994-07-27 1994-07-27 Improvements relating to cancer therapy
PCT/GB1995/001782 WO1996003515A2 (fr) 1994-07-27 1995-07-27 Expression en surface d'une enzyme dans la therapie genique a base de promedicaments

Publications (1)

Publication Number Publication Date
DK0774005T3 true DK0774005T3 (da) 2000-05-22

Family

ID=10758973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95927025T DK0774005T3 (da) 1994-07-27 1995-07-27 Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi

Country Status (15)

Country Link
US (2) US6025340A (fr)
EP (3) EP0772455B1 (fr)
JP (3) JPH10505335A (fr)
AT (3) ATE423208T1 (fr)
AU (2) AU712383B2 (fr)
CA (2) CA2196051A1 (fr)
DE (3) DE69514234T2 (fr)
DK (1) DK0774005T3 (fr)
ES (1) ES2143641T3 (fr)
GB (1) GB9415167D0 (fr)
GR (1) GR3032744T3 (fr)
NZ (2) NZ290449A (fr)
PT (1) PT774005E (fr)
WO (2) WO1996003151A2 (fr)
ZA (2) ZA956263B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37736E1 (en) 1992-05-05 2002-06-11 Automotive Technologies International Inc. Vehicle occupant position and velocity sensor
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2211293A1 (fr) * 1997-07-23 1999-01-23 Immunova Ltee Analogues de lysostaphine recombinants
JP2001512830A (ja) 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
EP1240922B1 (fr) * 1997-08-08 2008-11-12 Celmed Oncology (USA), Inc. Méthodes et composés de combattre la résistance à la thérapie biologique et chimique
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
IL137164A0 (en) * 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
CA2319468A1 (fr) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Sensibilisation de cellules a des composes utilisant un apport de gene et de compose induit par lipides
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU763020B2 (en) * 1998-03-06 2003-07-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
CN1367704A (zh) * 1999-04-30 2002-09-04 K·布朗特 用于基因疗法和转移的预防以及肿瘤的基因疗法的药剂
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US6656917B1 (en) * 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
BR0012676A (pt) * 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
GB0011060D0 (en) * 2000-05-08 2000-06-28 Cancer Res Campaign Tech Improvements relating to gene directed enzyme prodrug therapy
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
AU2002241911B9 (en) 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
NZ537690A (en) 2002-07-15 2009-07-31 Univ Texas Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
US20050107320A1 (en) * 2003-01-30 2005-05-19 Matthew During Methods and compositions for use in interventional pharmacogenomics
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
KR101502267B1 (ko) 2007-11-09 2015-03-18 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
EP0387380A1 (fr) 1989-03-17 1990-09-19 BEHRINGWERKE Aktiengesellschaft Mutants de l'activateur du plasminogène dérivé de l'urine, leur production et leur utilisation
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8920011D0 (en) 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US5633158A (en) 1991-10-23 1997-05-27 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
ATE361759T1 (de) 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
GB9315494D0 (en) 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9423367D0 (en) * 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy

Also Published As

Publication number Publication date
DE69534599T2 (de) 2006-07-20
DE69535916D1 (de) 2009-04-02
WO1996003151A2 (fr) 1996-02-08
EP0774005B1 (fr) 1999-12-29
EP0772455A2 (fr) 1997-05-14
DE69514234D1 (de) 2000-02-03
DE69534599D1 (en) 2005-12-15
NZ290448A (en) 1998-01-26
EP0919622B1 (fr) 2009-02-18
EP0919622A2 (fr) 1999-06-02
ES2143641T3 (es) 2000-05-16
EP0772455B1 (fr) 2005-11-09
AU693584B2 (en) 1998-07-02
GR3032744T3 (en) 2000-06-30
NZ290449A (en) 1998-08-26
JPH10503646A (ja) 1998-04-07
JP3747290B2 (ja) 2006-02-22
CA2196052A1 (fr) 1996-02-08
ZA956264B (en) 1996-03-15
ATE188256T1 (de) 2000-01-15
AU712383B2 (en) 1999-11-04
JPH10505335A (ja) 1998-05-26
EP0774005A1 (fr) 1997-05-21
DE69514234T2 (de) 2000-07-13
ATE308999T1 (de) 2005-11-15
US6004550A (en) 1999-12-21
US6025340A (en) 2000-02-15
AU3119195A (en) 1996-02-22
WO1996003515A3 (fr) 1996-03-07
WO1996003515A2 (fr) 1996-02-08
WO1996003151A3 (fr) 1996-05-02
AU3119095A (en) 1996-02-22
GB9415167D0 (en) 1994-09-14
EP0919622A3 (fr) 1999-10-06
ZA956263B (en) 1996-05-22
CA2196051A1 (fr) 1996-02-08
JP2006042821A (ja) 2006-02-16
ATE423208T1 (de) 2009-03-15
PT774005E (pt) 2000-06-30

Similar Documents

Publication Publication Date Title
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
BR9910251A (pt) Estimulação hematopoiética
IL181695A0 (en) Methods for cultivating cells and propagating viruses
MY114140A (en) Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy.
MY127047A (en) Disposable diaper
ZA97657B (en) Ligand directed enzyme prodrug therapy.
ZA906531B (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas
AU8239298A (en) Nucleotide-comprising composition
DE69022778D1 (de) Zellkultursubstrat, Bioreaktor mit Zellkultursubstrat und therapeutische Vorrichtung vom extrakorporalen Umlauftyp.
EP0373107A3 (fr) Utilisation d'enzymes de Auréobasidium pullulans pour le blanchiment de pâte
SE0103276D0 (sv) Anordning för administrering av salva till en hudyta
EP0227604A3 (fr) Emploi d'oligopeptides dans le traitement d'infections virales
DK1237537T3 (da) Præparat i form af en gel til modtagelse af et aktivt stof i oplösning eller suspension, især til anvendelse på en slimhinde, og fremgangsmåde til dets fremstilling
AU2944100A (en) Gene therapeutics
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
WO2000076453A3 (fr) Mort cellulaire assistee par emzymes
WO1987003883A3 (fr) Emploi d'oligopeptides dans le traitement d'infections virales